Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FSTX

F-star Therapeutics (FSTX) Stock Price, News & Analysis

F-star Therapeutics logo

About F-star Therapeutics Stock (NASDAQ:FSTX)

Key Stats

Today's Range
$7.12
$7.12
50-Day Range
$4.42
$7.12
52-Week Range
$2.07
$7.12
Volume
N/A
Average Volume
709,213 shs
Market Capitalization
$156.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Receive FSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FSTX Stock News Headlines

Astria Therapeutics price target raised to $28 from $26 at Oppenheimer
Lake Street Remains a Buy on Aquestive Therapeutics (AQST)
Do this if you missed cheap Bitcoin
Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this... Because a new blockchain is taking the world by storm… It’s seeing rapid adoption amongst crypto fans… And just now starting to break into the mainstream. While I cannot promise future returns or against losses… This might not just be another chance at Bitcoin-like gains… It could be EVEN bigger. But this market is moving fast… So if you want a shot at getting in on what could be the ground floor
Bicara Therapeutics Rises 39% in Debut on Nasdaq
See More Headlines

FSTX Stock Analysis - Frequently Asked Questions

F-star Therapeutics, Inc. (NASDAQ:FSTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.06. The firm earned $0.75 million during the quarter, compared to analyst estimates of $7.18 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that F-star Therapeutics investors own include New Age Brands (NF), Aurora Cannabis (ACB), Trican Well Service (TCW), Meta Platforms (META), NIO (NIO), Plug Power (PLUG) and Copper Mountain Mining (CMMC).

Company Calendar

Last Earnings
11/10/2021
Today
11/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FSTX
Employees
84
Year Founded
N/A

Profitability

Net Income
$-31,280,000.00
Pretax Margin
-213.97%

Debt

Sales & Book Value

Annual Sales
$21.17 million
Book Value
$4.70 per share

Miscellaneous

Free Float
21,279,000
Market Cap
$156.50 million
Optionable
Not Optionable
Beta
0.85
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:FSTX) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners